VolRC RAS scientific journal
RuEn

Journal section "Sectoral economic studies"

Catching-Up and Outstripping Development of the Russian Pharmaceutical Industry

Gusev A.B., Yurevich M.A.

Volume 16, Issue 6, 2023

Gusev A.B., Yurevich M.A. (2023). Catching-up and outstripping development of the Russian pharmaceutical industry. Economic and Social Changes: Facts, Trends, Forecast, 16(6), 55–73. DOI: 10.15838/esc.2023.6.90.3

DOI: 10.15838/esc.2023.6.90.3

Abstract   |   Authors   |   References
  1. Abdikeev N.M. (2022). Implementation of plans for import substitution in high-tech sectors of domestic industry in the context of external sanctions. Nauchnye trudy Vol'nogo ekonomicheskogo obshchestva Rossii, 235(3), 202–214 (in Russian).
  2. Balatsky E.V., Ekimova N.A. (2019). Innovation-technology matrices and national economic development strategies. Upravlenets – The Manager, 10(5), 9–19. DOI: 10.29141/2218-5003-2019-10-5-2 (in Russian).
  3. Balatsky E.V., Ekimova N.A. (2023). Antifragility of the national economy: A heuristic assessment. Journal of New Economy, 24(2), 28–49. DOI: 10.29141/2658- 5081-2023-24-2-2
  4. Bereznoy A.V. (2022). Transformation of Big Pharma business models. Mirovaya ekonomika i mezhdunarodnye otnosheniya=World Economy and International Relations, 66(3), 81–89. DOI: 10.20542/0131-2227-2022-66-3-81-89 (in Russian).
  5. Crespi F., Caravella S., Menghini M., Salvatori C. (2021). European technological sovereignty: An emerging framework for policy strategy. Intereconomics, 56(6), 348–354.
  6. DiMasi J.A., Grabowski H.G., Hansen R.W. (2016). Innovation in the pharmaceutical industry: new estimates of R&D costs. Journal of Health Economics, 47, 20–33. DOI: 10.1016/j.jhealeco.2016.01.012
  7. Dorzhieva V.V. (2022). State policy of import substitution as a factor in the development of the pharmaceutical industry in Russia: Impact of sanctions and steps to success. Vestnik Instituta ekonomiki Rossiiskoi akademii nauk, 6, 68–78. DOI: 10.52180/2073-6487_2022_6_68_78 (in Russian).
  8. Dorzhieva V.V. (2023). The strategy of the new industrialization of the pharmaceutical industry: national priorities and new challenges. Nauchnye trudy Vol'nogo ekonomicheskogo obshchestva Rossii, 240(2), 198–215. DOI: 10.38197/2072-2060-2023-240-2-198-215 (in Russian).\
  9. Dosi G., Marengo L., Staccioli J., Virgillito M.E. (2023). Big Pharma and monopoly capitalism: A long-term view. Structural Change and Economic Dynamics, 65, 15–35. DOI: https://doi.org/10.1016/j.strueco.2023.01.004
  10. Groshkova T., Liem M., Cunningham A., Sedefov R., Griffiths P. (2021). Drug-related violence: Will COVID-19 drive better data for safer and more secure EU? The International Journal on Drug Policy, 93, 103143. DOI: 10.1016/j.drugpo.2021.103143
  11. Gulin K.A., Mazilov E.A., Ermolov A.P. (2015). Import substitution as a tool to enhance social-economic development of territories. Problemy razvitiya territorii=Problems of Territory's Development, 3, 7–25 (in Russian).
  12. Gusev A.B., Yurevich M.A. (2023). The sovereignty of Russia in the area of pharmaceuticals: Challenges and opportunities. Terra Economicus, 21(3), 6–31. DOI: 10.18522/2073-6606-2023-21-3-6-31 (in Russian).
  13. Keenan L., Monteath T., Wójcik D. (2023). Patents over patients? Exploring the variegated financialization of the pharmaceuticals industry through mergers and acquisitions. Competition & Change, 27(3–4), 472–494. DOI: 10.1177/1024529422110785
  14. Komarova A.V., Petrov A.M. (2016). The strategy of import substitution as a factor in increasing the competitiveness of pharmaceutical companies. Rossiiskii vneshneekonomicheskii vestnik=Russian Foreign Economic Journal, 4, 51–62 (in Russian).
  15. Kotlyarova S.N., Lavrikova Yu.G., Averina L.M. (2017). The role of industrial production localization in the import substitution policy. Ekonomicheskie i sotsial'nye peremeny: fakty, tendentsii, prognoz=Economic and Social Changes: Facts, Trends, Forecast, 53(5), 115–127. DOI: 10.15838/esc.2017.5.53.8 (in Russian).
  16. Krestyaninov N.A. (2018). Analysis of government incentives for investments in the Russian pharmaceutical industry. Ekonomika: vchera, segodnya, zavtra=Economics: Yesterday, Today and Tomorrow, 8(8A), 63–77 (in Russian).
  17. Kruse S., Slomiany M., Bitar R. et al. (2014). Pharmaceutical R&D productivity: the role of alliance. Journal of Commercial Biotechnology, 20(2), 11–20. DOI: 10.5912/jcb632
  18. Litvinova A.V., Talalaeva N.S., Parfenova M.V. (2019). Development of methodological approaches to assessing the effectiveness of import substitution in Russia. Ekonomicheskie i sotsial'nye peremeny: fakty, tendentsii, prognoz=Economic and Social Changes: Facts, Trends, Forecast, 12(4), 67–85. DOI: 10.15838/esc.2019.4.64.5 (in Russian).
  19. Mamedyarov Z.A. (2017). Current trends and prospects of the Russian pharmaceutical industry and the foreign experience. MIR (Modernizatsiya. Innovatsii. Razvitie)=MIR (Modernization. Innovation. Research), 8(4), 772–780. DOI: 10.18184/2079-4665.2017.8.4.772-780 (in Russian).
  20. Meier C., Cairns-Smith S., Schulze U. (2013). Can emerging drug classes improve R&D productivity. Drug Discovery Today, 18, 607–609. DOI: 10.1016/j.drudis.2013.05.006
  21. Pammolli F., Magazzini L., Riccaboni M. (2011). The productivity crisis in pharmaceutical R&D. Nature Reviews Drug Discovery, 10(6), 428–438. DOI: 10.1038/nrd3405
  22. Pammolli F., Righetto L., Abrignani S. et al. (2020). The endless frontier? The recent in-crease of R&D productivity in pharmaceuticals. Journal of Translational Medicine, 18, 1–14. DOI: 10.1186/s12967-020-02313-z
  23. Park J.J., Grais R.F., Taljaard M. et al. (2021). Urgently seeking efficiency and sustainability of clinical trials in global health. The Lancet Global Health, 9(5), e681–e690. DOI: 10.1016/S2214-109X(20)30539-8
  24. Paul S.M., Mytelka D.S., Dunwiddie C.T. et al. (2010). How to improve R&D productivity: The pharmaceutical industry’s grand challenge. Nature Reviews Drug Discovery, 9(3), 203–214. DOI: 10.1038/nrd3078
  25. Redit C. (2022). Pharma backs off biotech acquisitions. Nature Biotechnology, 40, 1546–1550. DOI: 10.1038/s41587-022-01529-2
  26. Schuhmacher A., Hinder M., Stein A.V.S.et al. (2023). Analysis of pharma R&D productivity – a new perspective needed. Drug Discovery Today, 103726. DOI: 10.1016/j.drudis.2023.103726
  27. Vargason A.M., Anselmo A.C., Mitragotri S. (2021). The evolution of commercial drug delivery technologies. Nature Biomedical Engineering, 5(9), 951–967. DOI: 10.1038/s41551-021-00698-w
  28. Weigmann K. (2015). The ethics of global clinical trials. EMBO Reports, 16(5), 566–570. DOI: 10.15252/embr.201540398
  29. Wouters O.J., McKee M., Luyten J. (2020). Estimated research and development investment needed to bring a new medicine to market, 2009–2018. Jama, 323(9), 844–853. DOI: 10.1001/jama.2020.1166

Article views

all: , this year: , this month: , today:

Article downloads

all: , this year: , this month: , today:

View full article